Metformin and chronic renal impairment: A story of choices and ugly ducklings

Clinical Diabetes

Volumn 29, Issue 3, 2011, Pages 97-101

  Heaf, James G ^a   van Biesen, Wim ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BIGUANIDE; BUFORMIN; CITALOPRAM; DIAZEPAM; GLUCOSE; INSULIN; LACTIC ACID; METFORMIN; PHENFORMIN; PLACEBO; SULFONYLUREA DERIVATIVE;

ARTICLE; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG MECHANISM; EXERCISE; GLOMERULUS FILTRATION RATE; GLUCONEOGENESIS; GLUCOSE TRANSPORT; HUMAN; HYPOGLYCEMIA; INSULIN SENSITIVITY; INTESTINE ABSORPTION; LACTIC ACIDOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE PHOSPHORYLATION; PROGNOSIS; RISK FACTOR; TISSUE OXYGENATION; TISSUE PERFUSION; TRAFFIC ACCIDENT; UREMIA;

EID: 80051506430     PISSN: 08918929     EISSN: None     Source Type: Journal    
DOI: 10.2337/diaclin.29.3.97     Document Type: Article

References (32)

1. Bergman U, Boman G, Wiholm B-E: Epidemiology of adverse drug reactions to phenformin and metformin. BMJ 2:464-466, 1978
2. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE: Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 333:550-554, 1995
3. Cusi K, Consoli A, Defronzo RA: Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 81:4059-4067, 1996
4. Johansen K: Efficacy of metformin in the treatment of NIDDM. Diabetes Care 22:33-37, 1999
5. Velussi M, Cernigoi AM, Viezzoli L, Caffau C: Median-term (4 months) treatment with glibenclamide + metformin substituting for glibenclamide + phenformin lowers the lacticemia levels in type-2 diabetics (NIDDM). Clin Ter 141:483-492, 1992
6. Pilger E, Schmid P, Goebel R: Effect of biguanide therapy on lactate metabolism during graded submaximal ergometric testing. Acta Med Austriaca 5:91-95, 1978
7. DeFronzo RA, Goodman AM: Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 333:541-549, 1995
8. Luft D, Schmülling RM, Eggstein M: Lactic acidosis in biguanide-treated diabetics. Diabetologia 14:75-87, 1978
9. Garland PB, Newsholme EA, Randle PJ: Regulation of glucose uptake by muscle. Biochem J 93:665-678, 1964
10. Berger M, Hagg SA, Goodman MN, Ruderman NB: Glucose metabolism in perfused skeletal muscle. Biochem J 15:191-202, 1976
11. Wahren J, Hagenfeldt L, Felig P: Splanchnic and leg exchange of glucose, amino acids, and free fatty acids during exercise in diabetes mellitus. J Clin Invest 55:1303-1314, 1975
12. Berger M, Berchtold P, Cüppes JH: Metabolic and hormonal effects of muscular exercise in juvenile type diabetes. Diabetologia 13:355-365, 1977
13. Brown JB, Pedula K, Barzilay J, Herson MK, Latare P: Lactate acidosis rates in type 2 diabetes. Diabetes Care 21:1659-1663, 1998
14. Aguilar C, Reza A, Garcia JE, Rull JA: Biguanide related lactic acidosis: incidence and risk factors. Arch Med Res 23:19-24, 1992
15. Bodmer M, Meier C, Krähenbühl S, Jick SS, Meier CR: Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia. Diabetes Care 31:2086-2091, 2008
16. Campbell IW: Metformin and the sulphonylureas: the comparative risk. Horm Metab Res Suppl 15:105-111, 1985
17. Lalau JD, Lacroix C, Compagnon P, de Cagny B, Rigaud JP, Bleichner G, Chauveau P, Dulbecco P, Guérin C, Haegy JM, Loirat P, Marchand B, Ravaud Y, Weyne P, Fournier A: Role of metformin accumulation in metformin-associated lactic acidosis. Diabetes Care 18:779-784, 1995
18. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE: Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Arch Intern Med 163:2594-2602, 2003
19. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE: Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 4:CD002967, 2010
20. Eurich DT, Tsuyuki RT, Majumdar SR, McAlister FA, Lewanczuk R, Shibata MC, Johnson JA: Metformin treatment in diabetes and heart failure: when academic equipoise meets clinical reality. Trials 10:12-18, 2009
21. Sulkin TV, Bosman D, Krentz AJ: Contraindications to metformin therapy in patients with NIDDM. Diabetes Care 20:925-928, 1997
22. Holstein A, Nahrwold D, Hinze S, Egbert EH: Contraindications to metformin therapy are largely disregarded. Diabet Med 16:692-696, 1999
23. Kreiserg RA: Lactate homeostasis and lactic acidosis. Ann Intern Med 92 (Part 1):227-237, 1980
24. Lloyd MH, Iles RA, Simpson BR, Strunin JM, Layron JM, Cohen RD: The effect of stimulated metabolic acidosis on intracellular pH and lactate metabolism in the isolated perfused rat liver. Clin Sci Mol Med 45:543-549, 1973
25. Yudkin J, Cohen RD, Slack B: The haemodynamic effects of metabolic acidosis in the rat. Clin Sci Mol Med 50:177-184, 1976
26. Lambert H, Isnard F, Delorme N, Claude D, Bollaert PE, Straczek J, Larcan A: Physiopathological approach to pathological hyperlactatemia in the diabetic patient: value of blood metformin. Ann Fr Anest Reanim 6:88-94, 1987
27. U.K. Prospective Diabetes Study Group: Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
28. Holman RR, Paul SK, Bethel A, Mathews DR, Niel HAW: 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577-1589, 2008
29. Mani MK: Metformin in renal failure: weigh the evidence. Nephrol Dial Transplant 24:2287-2288, 2009
30. Wilholm B-E, Myrhed M: Metformin-associated lactic acidosis in Sweden 1977-1991. Eur J Clin Pharm 44:589-591, 1993
31. Stang M, Wysowski DK, Butler-Jones D: Incidence of lactic acidosis in metformin users. Diabetes Care 22:925-927, 1999
32. Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA: Lactate acidosis in patients with diabetestreated with metformin. N Engl J Med 338:265-266, 1998